Quenching methods for red blood cell inactivation process

Details Quenching methods for red blood cell inactivation process Quenching methods for red blood cell inactivation process

2005-10-31

2010-02-02

Saucier, Sandra E (Department: 1651)

Chemistry: molecular biology and microbiology

Maintaining blood or sperm in a physiologically active state...

Reexamination Certificate

active

07655392

ABSTRACT:
Methods are provided for improved quenching of undesired side reactions upon treating a red blood cell composition with a pathogen inactivating compound comprising a nucleic acid binding ligand and a functional group which is, or which is capable of forming, an electrophilic group. In some embodiments, the improved methods use a suitably high concentration of quencher that comprises a nucleophilic functional group that is capable of covalently reacting with the electrophilic group, wherein the treatment occurs within a desired pH range to provide sufficient quenching. Preferred quenchers for use in some of the methods include thiols, such as glutathione, which have been suitably neutralized such that addition to a red blood cell composition results in the desired concentration of quencher at a desirable pH range of 6.8 to 8.5.

REFERENCES:
patent: 2402665 (1946-06-01), Pepper et al.
patent: 4252645 (1981-02-01), Marconi et al.
patent: 4337269 (1982-06-01), Berke et al.
patent: 4727027 (1988-02-01), Wiesehahn et al.
patent: 4748120 (1988-05-01), Wiesehahn et al.
patent: 4944920 (1990-07-01), Rubinstein
patent: 4971760 (1990-11-01), Rubinstein
patent: 5055485 (1991-10-01), Geacintov et al.
patent: 5094960 (1992-03-01), Bonomo
patent: 5120649 (1992-06-01), Horowitz et al.
patent: 5232844 (1993-08-01), Horowitz et al.
patent: 5281579 (1994-01-01), Estep
patent: 5418130 (1995-05-01), Platz et al.
patent: 5559250 (1996-09-01), Cook et al.
patent: 5587490 (1996-12-01), Goodrich, Jr. et al.
patent: 5591350 (1997-01-01), Piechocki et al.
patent: 5601730 (1997-02-01), Page et al.
patent: 5637451 (1997-06-01), Ben-Hur et al.
patent: 5658722 (1997-08-01), Margolis-Nunno et al.
patent: 5660731 (1997-08-01), Piechocki et al.
patent: 5691132 (1997-11-01), Wollowitz et al.
patent: 5753258 (1998-05-01), Schreier et al.
patent: 6093725 (2000-07-01), Cook et al.
patent: 6136586 (2000-10-01), Budowsky
patent: 6143490 (2000-11-01), Cook et al.
patent: 6150109 (2000-11-01), Edson et al.
patent: 6171777 (2001-01-01), Cook et al.
patent: 6177441 (2001-01-01), Cook et al.
patent: 6270952 (2001-08-01), Cook et al.
patent: 6410219 (2002-06-01), Cook et al.
patent: 6514987 (2003-02-01), Cook et al.
patent: 6544727 (2003-04-01), Hei
patent: 6617157 (2003-09-01), Budowsky et al.
patent: 6709810 (2004-03-01), Cook et al.
patent: 6951713 (2005-10-01), Hei et al.
patent: 7293985 (2007-11-01), Cook et al.
patent: 2001/0009756 (2001-07-01), Hei et al.
patent: 2002/0182581 (2002-12-01), Cook et al.
patent: 2002/0192632 (2002-12-01), Hei et al.
patent: 2003/0113704 (2003-06-01), Stassinopoulos et al.
patent: 2004/0029897 (2004-02-01), Cook et al.
patent: 2004/0180321 (2004-09-01), Cook et al.
patent: 2004/0185544 (2004-09-01), Hei
patent: 0 352 076 (1990-01-01), None
patent: 0 352 076 (1990-01-01), None
patent: 0 457 196 (1991-11-01), None
patent: 0 641 796 (1995-03-01), None
patent: WO 95/00631 (1995-01-01), None
patent: WO 96/02838 (1996-02-01), None
patent: WO 96/09846 (1996-04-01), None
patent: WO 96/14737 (1996-05-01), None
patent: WO 96/39816 (1996-12-01), None
patent: WO 96/39818 (1996-12-01), None
patent: WO 96/40857 (1996-12-01), None
patent: WO 97/02028 (1997-01-01), None
patent: WO 97/07674 (1997-03-01), None
patent: WO 97/16966 (1997-05-01), None
patent: WO 97/18844 (1997-05-01), None
patent: WO 98/30545 (1998-07-01), None
patent: WO 99/34839 (1999-07-01), None
patent: WO 2006/050328 (2006-05-01), None
US 6,331,387, 12/2001, Hei (withdrawn)
Aejmelaeus, R. et al. (1996). “Is There an Unidentified Defense Mechanism Against Infection in Human Plasma,”FEBS Letters384:128-130.
Al-Harbi, M.M. et al. (1997). “Gentamycin and Cyclosporine Increase Total Soluble Thiols in the Plasma and Lymphocytes of Rats and Perturb Erythrocyte Fragility,”Med. Sci. Res. 25:155-157.
Awasthi, Y.C. et al. (Dec. 28, 1984). “Purification and Characterization of a New Form of Glutathione S-Transferase from Human Erythrocytes,”Biochemical and Biophys. Res. Commun.125:1053-1060.
Anonymous. (1971). Special Regents for Thiol Groups,Aldrichimica Acta4(3):33-35.
Anonymous. (1971). Special Regents for Thiol Groups,Aldrichimica Acta4(3):46-48.
Anonymous. (2003). “Helinx® Technology Inactivates Human T-Cell Leukemia Virus (HTLV I/II) in Human Red Blood Cells,” Abstractpresented at: American Association of Blood Banks(AABB), 56th Annual Meeting, Nov. 1-4, 2003, located at <http://www.cerus.com/index.cfm/abstracts/2003/Helinx174TechnologylnactivatesHumanTCell LeukemiaVirusH . . . >, last visited on Jan. 8, 2007, two pages.
Anonymous. (2003). “Helinx® Technology Inactivates Pathogens of Emerging Importance in Red Blood Cell Concentrates,” Abstractpresented at: American Society of Hematology(ASH).
45th Annual Meeting, Dec. 6-9, 2003, located at <http://www.cerus.com/index.cfm/abstracts/2003/Helinx174Technology InactivatesPathogensof EmergingImpor . . . >, last visited on Jan. 8, 2007, two pages.
Anonymous. (2003). “Treatment with Helina Technology Does Not Affect the Ability of Red Blood Cells to Overcome Oxidative Stress,” Abstractpresented at: American Association of Blood Banks(AABB), 56th Annual Meeting, Nov. 1-4, 2003, located at <http://www.cerus.com/index.cfm/abstracts/2003/Treatment withHelinx174TechnologyDoesNotAffecttheAbilit . . . >, last visited on Jan. 8, 2007, two pages.
Anonymous. (2004). “Antibody Formulation to S-303-Treated RBCs in Setting of Chronic RBC Transfusion,” Abstractpresented at:Ametican Society of Hematology(ASH), 46th Annual Meeting, Dec. 4-7, 2004, located at <http://www.cerus.com/index.cfm/abstracts/2004/AntibodyFormulationtoS303TreatedRBCsinS ettingofChronic . . . >, last visited on Jan. 8, 2007, two pages.
Anonymous. (2004). “Elimination of Immunoreactivity of Red Cells Treated with a Modified S-303 Pathogen Inactivation Process,” Abstractpresented at: American Society of Hematology(ASH), 46th Annual Meeting, Dec. 4-7, 2004, located at <http://www.cerus.com/index.cfm/abstracts/2004/EliminationofImmunoreactivityofRedCellsTreatedwithaMod . . . >, last visited on Jan. 8, 2007, two pages.
Anonymous. (2004). “Transfusion of S-303 Treated RBCs to Treat Acute Anemia During or Following Cardiac Surgery: Results of a Phase III Trial,” Abstractpresented at:American Society of Hematology(ASH), 46th Annual Meeting, Dec. 4-7, 2004, located at <http://www.cerus.com/index.cfm/abstracts/2004/TransfusionofS303TreatedRBCsToTreatAcut eAnemiaduringor . . . >, last visited on Jan. 8, 2007, two pages.
Anonymous. (Dec. 3, 2004). “Cerus Corporation and Collaborators to Present at American Society of Hematology Meeting,”Press Release, Cerus Corporation, located at <http://www.cerus.com/index.cfm/News/Press—Release—Archive?Year=2007&NID=8..>, last visited on Jan. 8, 2007, four pages.
Baxt, B. et al. (1976). “Mechanisms of Vesicular Stomatitis Virus-Induced Cytopathic Effects,”Virology72:383-392.
Begleiter, A. et al. (1996). “Chlorambucil in Chronic Lymphocytic Leukemia: Mechanism of Action,”Leukemia and Lymphoma23:187-201.
Beutler, E. et al. (Jun. 1982).“The Osmotic Fragility of Erythrocytes After Prolonged Liquid Storage and After Reinfusion,”Bloodvol. 59(6):1141-1147.
Bolton, M.G. et al. (May 1991). “Specificity of Isozymes of Murine Hepatic Gluthathione S-Transferase for the Conjugation of Glutathione with L-Phenylalanine Mustard,”Cancer Research51:2410-2415.
Bolton, M.G. et al. (1993). “Kinetic Analysis of the Reaction of Melphalan with Water, Phosphate, and Glutathione,”Drug Metab. Dispos.21:986-996.
Bonadonna, G. et al. (1964). “Protection Studies with Sodium Thiosulfate Against Methyl bis(3-Chloroethyl)amine Hydrochloride (HN2) and its Ethylenimonium Derivative,”Clin. Pharm.&Thera6(1):50-64.
Budowsky, E.I. et al. (1996). “Principles of Selective Inactivation of the Viral Genome: Dependence of the Rate

Affiliated with

Also associated with

Rating

Quenching methods for red blood cell inactivation process does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Quenching methods for red blood cell inactivation process, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Quenching methods for red blood cell inactivation process will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4209362